TY - JOUR T1 - Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial JO - Journal of Clinical Oncology UR - https://eprints.whiterose.ac.uk/171150/ PY - 2020/12/01 AU - Eisen T AU - Frangou E AU - Oza B AU - Ritchie AWS AU - Smith B AU - Kaplan R AU - Davis ID AU - Stockler MR AU - Albiges L AU - Escudier B AU - Larkin J et al ED - DO - DOI: 10.1200/jco.20.01800 PB - American Society of Clinical Oncology (ASCO) VL - 38 IS - 34 SP - 4064 EP - 4075 Y2 - 2025/07/16 ER -